Skip to main content
STAA logo

STAA · Staar Surgical Co

Track STAA — free
$25.09 -0.26 (-1.03%)
Market Cap
$1.27B
Shares
50.20M
Volume · Nov 18 451.31K Avg daily vol (3M) 844.74K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$25.35 Open$25.30 Day$25.02–25.75 52W close$16.10–33.34 Avg vol 30d712K Short int3.6M · 7.3% of shares · 6.8d Short vol49% Last earningsNov 4, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 4

Up next

Dec 30, 2026 Est · unconfirmed · in 6 wks

Latest documents

2026
Nov 10
Investor event
China growth and gross-margin recovery gain support

Star Surgical management expects Q4 China revenue growth as supply improves and V5 and torque mix rises, while lower unit costs and reduced tariffs support gross-margin recovery. A 20% adjusted EBITDA margin is viewed as achievable going forward.

5 source passages
Really excited to have Star Surgical here at the conference this year. That's right. And that's all China, of course. We had 13% growth ex-China, and that's both volume and price. So mix is higher torque and higher V5. That's happening in Q4. So those two factors, lower unit costs and reduced tariffs, will significantly improve our gross margins going forward. 20% is a nice round number that we can target going forward, and we should be able to achieve that kind of level. Open the document at this passage
Nov 4
Earnings call
Third-quarter sales rose 21% excluding China deferrals

Star Surgical reported third-quarter net sales of $83.4 million, down 12% from the prior year but up 21% excluding $25.9 million of China deferred sales. Gross margin was 70.9%, and adjusted EBITDA was $14.4 million.

6 source passages
Star Surgical Third Quarter 2026 results call Third quarter net sales were 83.4 million, down 12% from the prior year quarter. Excluding the China deferred sales, prior year third quarter net sales were 68.8 million. Against that base, our third quarter 2026 net sales increased 21%. The prior year quarter included 25.9 million of deferred China sales, which I'll refer to as the China deferred sales. third quarter gross profit margin was 70.9% compared with 82.2% in the prior year quarter. Adjusted EBITDA for the third quarter was $14.4 million, or $0.28 per diluted share, compared with $34.7 million, or $0.69 per diluted share in the prior year quarter. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Oct 2
Sales rose 21% adjusted as gross margin fell to 70.9%

STAAR Surgical Company reported third-quarter net sales of $83.4 million, up 21% excluding the prior year's $25.9 million China shipment, while gross margin fell to 70.9% and net income was $5.6 million.

Revenue $83.41M ▼ 12.0% Net income $5.58M ▼ 37.2% Diluted EPS $0.11 ▼ 38.9%
Read from the MD&A section
4 source passages
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. For the three months ended October 2, 2026, net sales were $83.4 million, compared with $94.7 million during the same period last year, a decrease of 12%. Third-quarter 2025 net sales included $25.9 million associated with delayed revenue recognition of an order placed and shipped in 2024 (the “December China Shipment”). Excluding that amount, the prior-year comparison base would have been $68.8 million, against which third-quarter 2026 net sales would have increased 21%. Gross profit margin decreased to 70.9% of revenue for the three months ended October 2, 2026 compared to 82.2% of revenue for the three months ended September 26, 2025. Net income for the third quarter of 2026 was $5.6 million or $0.11 per diluted share, down from net income of $8.9 million or $0.18 per diluted share for the prior year quarter. Open the document at this passage
Nov 4
Current report 8-K
Third-Quarter Net Sales Fall 12% to $83.4 Million on Prior-Year China Deferral

STAAR Surgical reported third-quarter 2026 net sales of $83.4 million, down 12% from $94.7 million, as the prior-year quarter included $25.9 million of deferred China sales. Net income was $5.6 million, or $0.11 per diluted share, and cash, cash equivalents, and investments reached $206.4 million. The Board authorized a $50 million share repurchase program in September 2026.

Financial results, Regulation FD disclosure Read from the first part of this long document
5 source passages
STAAR delivered third-quarter net sales of $83.4 million, a 12% decrease from $94.7 million in the same period last year. The prior-year quarter included $25.9 million of previously deferred China sales Net income for the third quarter of 2026 was $5.6 million, or $0.11 per diluted share Cash, cash equivalents, and investments available for sale as of October 2, 2026, totaled $206.4 million the Board authorized a share repurchase program under which the Company may repurchase up to $50 million of its outstanding common stock. Open the document at this passage
Oct 5
Current report 8-K/A Events of Sep 8
Director or officer change, or executive pay, Regulation FD disclosure

STAAR Surgical Company appointed David Bailey as Chief Commercial Officer effective September 8, 2026; the amendment corrects his $850,000 initial equity award to 50% RSUs and 50% stock options, with a separate $1,400,000 award split equally.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$328.27M
Trailing 12 months
Net income (TTM)
$530,000
Trailing 12 months
Revenue growth YoY
-12.0%
Year over year
Operating margin
0.2%
Trailing 12 months
P / E (TTM)
2,535.0
Trailing earnings · reciprocal yield 0.0%
FCF yield
1.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$206.41M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.8%
Year over year · more shares
Price change (1Y)
-1.2%
Trailing year
Short interest
7.3%
Latest settlement · 6.8 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 4, 2026
Q3 FY26

TL;DR. STAAR delivered record nine-month revenue and positive free cash flow, underlying quarterly sales growth of 21%, strong regional performance outside China, continued China share gains and progress on presbyopia and market access, supported by $206.4 million of cash and investments, no debt and a $50 million repurchase authorization. Risks include gross-margin and tariff pressure, elevated unit costs, insufficient China supply, regional weakness, sequentially lower fourth-quarter China revenue and withheld broader guidance.

Bullish
  • + Third-quarter net sales increased 21% to $83.4 million after excluding $25.9 million of deferred China sales recognized in the prior-year quarter. new
Bearish
  • − Reported third-quarter net sales declined 12% to $83.4 million because the prior-year quarter included $25.9 million of deferred China sales. new
  • − Japan and South Korea declined year over year due to currency headwinds and overall market weakness. new
  • − U.S.-origin China inventory remains exposed to tariffs despite the transition to Swiss manufacturing. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Neutral Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +6%
above
Price vs 50-day avg +10%
above
RSI (14) 54
neutral
MACD trend Negative
52-week position 54%
mid-range
Momentum
relative strength
Neutral
1-month return +17%
trailing
6-month return −15%
trailing
YTD return +10%
this year
Relative strength −12%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $23 › 200d $24 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.27% of shares out · ▼ -1.2% MoM · 6.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
197 holders — mid 3-yr range
Squeeze score 72
high risk · 0–100
Fundamentals
Weak
Revenue growth −24%
Y/Y
Gross margin 76%
contracting
EPS growth −295%
Y/Y
Free cash flow $-40.1M
Valuation P/E 2535
rich
Buyback $50.0M
authorized
Quant / Vol
risk profile
Very High
Volatility 57%
annualized · 1-yr
Max drawdown −43%
past year
ATR 4.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 6
Latest guidance · from the 8-K filed Nov 4, 2026
the start of the year
Operating expense target $225M
the year
Operating expense target $225M
Guided vs delivered · last 6 settled
Net sales fiscal year 2024
guided $340M – $345M
$313.9M Miss −8.4%
Net sales 1Q24
guided $72M
$77.36M Beat +7.4%
Net sales fiscal 2023
guided $340M
$322.42M Miss −5.2%
Net sales fiscal 2022
guided $295M
$239.44M Miss −18.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+6% Bullish
Price vs 50-day avg
+10% Bullish
RSI (14)
54 Neutral
MACD trend
Negative Bearish
52-week position
54% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $23 › 200d $24 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +34 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.27% of shares out · ▼ -1.2% MoM · 6.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
197 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $16 Now $25 · 54% Range high $33
vs 200-day avg +6% vs 50-day avg +10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $20M Q2 2026 —
Adjusted EBITDA per diluted share non-GAAP $0.39 Q2 2026 —
Americas sales growth Y/Y 12% Q2 2026 —
APAC sales growth Y/Y 189% Q2 2026 —
China sales $52.3M Q2 2026 —
EMEA sales growth Y/Y -1% Q2 2026 —
Global Sales Growth (Constant Currency) non-GAAP 114.8% Six Months Ended July 3, 2026 —
Gross margin 74.5% Q2 2026 —
Net sales excluding China $41.2M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
STAA
Staar Surgical Co
this stock
$1.27B +9.8% -23.7% 2535.0 7.3%
ISRG
Intuitive Surgical Inc
$145.92B -25.7% +20.5% 51.0 2.0%
BDX
Becton Dickinson & Co
$58.86B — +8.2% 95.6 3.0%
MDLN
Medline Inc.
$51.51B -6.8% +11.5% — 2.9%
ALC
Alcon Inc
$36.15B -4.5% +10.5% — 3.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
197
% held
100.5%
Net QoQ
-4.7M sh
Top holder
BROADWOOD CAPITAL INC
Held Float
View
Held by Funds
Fund positions
215
View
Short & Settlement
Short Interest Falling
Shares short
3.6M
Days to cover
6.8d
Change
-46.2K sh
View
Short Volume
Short vol %
49%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
632
Value
$16.0K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
36.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$239.4M
Net income (FY)
$-80.4M
EPS diluted
$-1.62
View
Buybacks
Authorized
$50.0M
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 10, 2026
This year
24

Star Surgical management expects Q4 China revenue growth as supply improves and V5 and torque mix rises, while lower unit costs and reduced tariffs support gross-margin recovery. A 20% adjusted EBITDA margin is viewed as achievable going forward.

View
Proposed Sales
Value
$362.5K
Shares
13.5K
Filed
Aug 5, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
STAAR Surgical Reports Third Quar…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
STAA -5.0% +17.3% -15.2% +3.3% +9.8%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -1.1% +22.9% -11.7% +6.7% +2.7%

Capital returns

Buyback program · as of Nov 4, 2026
Authorized
$50.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 718937 CUSIP 852312305 13F (30d) 211 filings 183 filers Visit website Investor relations